SGLT-2 inhibitors for patients with heart failure: What have we learned recently?
Office of the Provost; Cardiology
Purpose of review: In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.
Recent findings: Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms. SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.
Publication ( Name of Journal)
Current atherosclerosis reports
Rifai, M. A.,
Newby, L. K.,
Nair, A. P.,
Rogers, J. G.,
Virani, S. S.
(2022). SGLT-2 inhibitors for patients with heart failure: What have we learned recently?. Current atherosclerosis reports, 24(8), 627-634.
Available at: https://ecommons.aku.edu/provost_office/112